Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
April 7, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
doctor holding red stethoscope

Photo by Online Marketing on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Insuring a U.S. family now costs nearly $27,000 a year — driven primarily by prices, not overuse — with hospital procedures running 2–3x more than peer nations (hip replacement: $29K in the U.S. vs. $11K abroad)
  • Drug prices are dramatically higher: Herceptin costs $6,819 per injection in the U.S. vs. $1,360 in the UK; Eliquis runs $513 for 60 pills vs. $90 in Germany — because the U.S. government generally doesn’t force drugmakers to accept lower rates
  • Hospital consolidation is a key culprit: 43% of U.S. general hospitals now operate in highly or monopolistically concentrated markets, giving systems leverage to extract higher insurance rates
  • Administrative costs consume 25% of U.S. healthcare spending — far above peer nations — while U.S. physicians earn a mean of $245K annually, roughly double their European counterparts

What Happened?

A new WSJ analysis drawing on data from the International Federation of Health Plans, the Health Care Cost Institute, and the OECD breaks down the structural reasons U.S. healthcare spending towers above every other developed nation. The core driver is price: Americans pay two to three times more than peer nations for the same surgeries, the same drugs, and the same clinical labor. Hospital consolidation has given health systems leverage to extract higher rates from insurers, while the absence of government drug price controls allows pharmaceutical companies to charge whatever the market will bear. Administrative overhead — billing, claims processing, and customer service — consumes 25 cents of every healthcare dollar.

Why It Matters?

The cost gap is not merely an economic curiosity — it translates directly into coverage gaps, medical debt, and foregone care for millions of Americans. Insuring a family now costs as much as buying a car each year. American physicians earn a mean of $245,000 annually versus roughly $99,000 in the UK, and U.S. nurses earn $97,000 versus $53,000 in the UK — compensation gaps that reflect the pricing power of a consolidated, opaque market. Healthcare utilization has also risen sharply in recent years, driven by costly new GLP-1 weight-loss drugs and increased hospital use, adding fuel to an already expensive system.

What’s Next?

Most of these structural drivers — hospital consolidation, lack of drug price regulation, and high administrative overhead — are deeply entrenched and would require significant legislative or regulatory action to address. The Trump administration has signaled interest in drug pricing reform, and the FTC has continued scrutinizing hospital mergers, but no comprehensive overhaul is on the immediate horizon. As healthcare spending continues to climb as a share of GDP, pressure on employers, insurers, and policymakers to confront the underlying price dynamics is likely to intensify regardless of which party controls Washington.

Source: The Wall Street Journal

Previous Post

Trump Floats Seizing Iran’s Oil Fields — With One Eye on China

Next Post

Anthropic Bets $200M on Private Equity Push to Bring AI Into Corporate America

Recommended For You

FDA Orders Vision-Loss Warnings on Every GLP-1 Drug After Trials Show NAION Rates of 6.4 vs. 3.8 per 100,000 Patient-Years

by Team Lumida
7 days ago
Bernie Sanders Pushes for Cheaper Wegovy: Can Novo Nordisk Resist?

The FDA will require all GLP-1 drugs, including Wegovy and Zepbound, to warn of a rare optic nerve condition that can cause sudden, permanent vision loss.

Read more

Lilly’s Foundayo Pill Cuts Sleep Apnea Severity by 43.8% in a Late-Stage Trial, Setting Up an FDA Filing by Year-End

by Team Lumida
1 week ago

Eli Lilly’s Foundayo pill cut sleep apnea events by 21.1 an hour vs. 4.8 on placebo, and Lilly plans to seek U.S. approval by year-end.

Read more

AI-Discovered Drug Reverses Biological Aging by Up to 6 Years in Mid-Stage Trial, Nature Biotechnology Study Finds

by Team Lumida
2 months ago
AI Investment Boom: How Tech Giants Are Leading the Charge

Insilico Medicine's rentosertib — an AI-designed lung disease drug — reduced biological age by up to six years in a 42-patient mid-stage trial, per a Nature Biotechnology study,...

Read more

Oura Faces Class-Action Over Sleep Data Accuracy — And the Whole Wearables Industry Is Watching

by Team Lumida
2 months ago
person clicking Apple Watch smartwatch

A proposed class-action lawsuit alleges Oura's ring failed to reliably track sleep — raising questions about the gap between wearable health trackers' marketing promises and what their data...

Read more

Employer Healthcare Costs Projected to Rise 9.5% in 2027 — Fourth Consecutive Year of Near-Double-Digit Increases

by Team Lumida
3 months ago
doctor holding red stethoscope

Average healthcare costs are projected to reach more than $19,000 per employee in 2027, a 9.5% year-over-year increase, according to Aon. This marks the fourth consecutive year of...

Read more

US Alcohol Consumption Holds at Historic Low as Majority of Americans Now Say Drinking Is Bad for Health

by Team Lumida
3 months ago
clear drinking glass with ice cubes

A Gallup poll of 1,200 adults finds 54% of Americans consume alcohol — matching last year's historic low and halting three consecutive annual declines — while 51% now...

Read more

Big Food’s GLP-1 Reckoning: Conagra, Kraft, and Packaged-Food Giants Reformulate for the Not-So-Hungry

by Team Lumida
3 months ago
pasta with red sauce on white ceramic round plate

As GLP-1 weight-loss drugs suppress appetite across millions of households, packaged-food companies are retooling recipes, portion sizes, and sensory profiles to win over consumers who eat less but...

Read more

Novo Nordisk Tests Low-Dose Wegovy Pills as Most Patients Already Stick to Smallest Doses

by Team Lumida
3 months ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has launched a 450-person trial to determine the minimum effective dose of its oral Wegovy pill — a clinically significant shift given that more than two-thirds...

Read more

4 in 5 Americans Say Healthcare Costs Are the Nation’s Top Health Problem — and Nobody Agrees on Who Should Fix It

by Team Lumida
3 months ago
doctor holding red stethoscope

A Commonwealth Fund survey of 25,873 adults finds near-universal alarm over health insurance premiums and out-of-pocket costs, even as ACA marketplace premiums surge 58% in 2026 and nearly...

Read more

Wealthy, Healthy, and Ready to Spend: Baby Boomers Are Driving a Global Travel Boom the Industry Is Racing to Serve

by Team Lumida
3 months ago
couple kissing on the road during daytime

Baby boomers — flush with retirement savings and in better health than previous generations — are fueling a high-end travel surge, with the industry responding with private-plane tours,...

Read more
Next Post
Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Anthropic Bets $200M on Private Equity Push to Bring AI Into Corporate America

China’s Bold Economic Moves: What You Need to Know Now

How China Became Iran's Economic Lifeline — and Fueled Its War Machine

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Will September’s Fed Rate Cuts Surprise Investors? Here’s What Deutsche Bank Predicts

Fed’s Pivot Pause: Rate Cuts May Slow in 2025 as Inflation Persists

December 13, 2024
Microsoft’s AI Empire: Nadella’s Bold Moves and Billion-Dollar Bets

Microsoft’s Data-Center Crunch to Persist Into 2026

October 10, 2025
a close up of a human skull on a black background

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

July 20, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018